Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis

Andreas Wollenberg, Jonathan I. Silverberg, Franz J. Legat, Marie Tauber, Vivian T. Laquer, April W. Armstrong, Andrew E. Pink, Luigi Naldi, Grażyna Pulka, Jacek Zdybski, Athanasios Tsianakas, Jorge Diaz, Inese Svarca, Jennifer Beecker, Galina Balakirski, Sylvia Pauser, Liliana Ulianov, Anna Ryzhkova, Jean-Loup Machu, Christophe Piketty

Open source

DOI: 10.2340/actadv.v106.adv-2025-0085
Published: 2026-06-10
Container: Acta Dermato-Venereologica
Publisher: MJS Publishing, Medical Journals Sweden AB
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.2340/actadv.v106.adv-2025-0085,
  title = {Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1\&amp;2) in Patients with Moderate-to-Severe Atopic Dermatitis},
  author = {Andreas Wollenberg and Jonathan I. Silverberg and Franz J. Legat and Marie Tauber and Vivian T. Laquer and April W. Armstrong and Andrew E. Pink and Luigi Naldi and Grażyna Pulka and Jacek Zdybski and Athanasios Tsianakas and Jorge Diaz and Inese Svarca and Jennifer Beecker and Galina Balakirski and Sylvia Pauser and Liliana Ulianov and Anna Ryzhkova and Jean-Loup Machu and Christophe Piketty},
  year = {2026},
  journal = {Acta Dermato-Venereologica},
  doi = {10.2340/actadv.v106.adv-2025-0085},
  url = {https://doi.org/10.2340/actadv.v106.adv-2025-0085}
}

RIS

TY  - JOUR
TI  - Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&amp;2) in Patients with Moderate-to-Severe Atopic Dermatitis
AU  - Andreas Wollenberg
AU  - Jonathan I. Silverberg
AU  - Franz J. Legat
AU  - Marie Tauber
AU  - Vivian T. Laquer
AU  - April W. Armstrong
AU  - Andrew E. Pink
AU  - Luigi Naldi
AU  - Grażyna Pulka
AU  - Jacek Zdybski
AU  - Athanasios Tsianakas
AU  - Jorge Diaz
AU  - Inese Svarca
AU  - Jennifer Beecker
AU  - Galina Balakirski
AU  - Sylvia Pauser
AU  - Liliana Ulianov
AU  - Anna Ryzhkova
AU  - Jean-Loup Machu
AU  - Christophe Piketty
PY  - 2026
JO  - Acta Dermato-Venereologica
DO  - 10.2340/actadv.v106.adv-2025-0085
UR  - https://doi.org/10.2340/actadv.v106.adv-2025-0085
ER  -

APA

Wollenberg, A., Silverberg, J. I., Legat, F. J., Tauber, M., Laquer, V. T., Armstrong, A. W., Pink, A. E., Naldi, L., Pulka, G., Zdybski, J., Tsianakas, A., Diaz, J., Svarca, I., Beecker, J., Balakirski, G., Pauser, S., Ulianov, L., Ryzhkova, A., Machu, J., & Piketty, C. (2026). Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis. Acta Dermato-Venereologica. https://doi.org/10.2340/actadv.v106.adv-2025-0085

Source records

crossref · retrieved 2026-09-25T19:38:06.390Z

Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&amp;2) in Patients with Moderate-to-Severe Atopic Dermatitis

Credibility signals

Cite this work

BibTeX

RIS

APA

Source records

Efficacy and Safety of Nemolizumab at Week 48: Results from the Maintenance Phase of Two Global Phase 3 Pivotal Studies (ARCADIA 1&2) in Patients with Moderate-to-Severe Atopic Dermatitis